The present invention relates to a SMAC mimetic and pharmaceuticalcompositions thereof, morespecifically the present invention is directed to a Compound with a followingstructure:(see above formula)pharmaceutically acceptable salts and to pharmaceutical compositionscomprising it, and to their usealone or in combination in the treatment of proliferative disorders,comprising cancers. Further the presentinvention relates to pharmaceutical composition in a dosage unit forintravenous infusion that comprisesinternally administering to the patient a SMAC mimetic, their regimens anddosing for treating aproliferative disorder in a patient. The invention further includes thestimulation of the concomitantdegradation of of clAP1 and clAP2 in cancer cells.
